Heininger A, Jahn G, Engel C, Notheisen T, Unertl K, Hamprecht K
Klinik für Anästhesiologie und Transfusionsmedizin, Institut für Anästhesiologie, Universitätsklinikum Tübingen, Germany.
Crit Care Med. 2001 Mar;29(3):541-7. doi: 10.1097/00003246-200103000-00012.
To assess the occurrence of active human cytomegalovirus (HCMV) infection and HCMV disease and to evaluate potential risk factors in immunocompetent intensive care patients after major surgery or trauma.
A prospective clinical study.
An anesthesiological intensive care unit (ICU) in a university hospital.
Fifty-six anti-HCMV immunoglobulin G (IgG) seropositive patients without manifest immunodeficiency whose simplified acute physiology score (SAPS II) value rose to >or=41 points during their ICU stay.
Once a week, the patients were examined for active HCMV infection by polymerase chain reaction and by viral cultures from blood and lower respiratory tract secretions. Three times a week, detailed clinical examination for signs of HCMV disease was carried out.
Twenty of the 56 ICU patients (35.6%) who met the study criteria of a SAPS II score >40 points and anti-HCMV IgG seropositivity developed an active HCMV infection as diagnosed by the detection of HCMV DNA in leukocytes, plasma, or respiratory tract secretions. In seven patients, the virus was isolated in the respiratory tract secretions. Severe HCMV disease appeared in two patients with pneumonia or encephalitis respectively. In patients with active HCMV infection, the mortality tended to be higher (55%) than in those without (36%); the duration of intensive care treatment of the survivors was significantly longer in the patients with active HCMV infection (median 30 vs. 23 days; p = .0375). Univariate testing for factors associated with active HCMV infection showed the importance of sepsis at admission (p = .011) and prolonged pretreatment on the ward or in an external ICU (p = .002); the relevance of underlying malignant disease was borderline (p = .059). Multiple regression analysis identified only sepsis to be independently associated with active HCMV infection (p = .02; odds ratio, 4.62).
Even in a group of ICU patients without manifest immunodeficit who were anti-HCMV IgG seropositive and had reached a SAPS II score of >or=41 points, active HCMV infection occurred frequently (35.6%). Septic patients were affected twice as often as the total study population. In 2 of the 20 cases, active HCMV infection progressed to severe HCMV disease. Proper diagnosis demands special clinical attention combined with extended virological examinations. Further studies in a larger patient group should evaluate the influence of HCMV on ICU mortality.
评估大型手术或创伤后免疫功能正常的重症监护患者中活动性人巨细胞病毒(HCMV)感染及HCMV疾病的发生情况,并评估潜在风险因素。
一项前瞻性临床研究。
一所大学医院的麻醉重症监护病房(ICU)。
56例抗HCMV免疫球蛋白G(IgG)血清学阳性且无明显免疫缺陷的患者,其简化急性生理学评分(SAPS II)在ICU住院期间升至≥41分。
每周对患者进行一次聚合酶链反应检测及血液和下呼吸道分泌物病毒培养,以检查是否存在活动性HCMV感染。每周三次对患者进行详细临床检查,以查找HCMV疾病迹象。
56例符合SAPS II评分>40分及抗HCMV IgG血清学阳性研究标准的ICU患者中,20例(35.6%)经检测白细胞、血浆或呼吸道分泌物中存在HCMV DNA,确诊发生活动性HCMV感染。7例患者的呼吸道分泌物中分离出病毒。分别有2例患者出现严重的HCMV疾病,表现为肺炎或脑炎。活动性HCMV感染患者的死亡率倾向于高于未感染患者(55%对36%);存活患者中,活动性HCMV感染患者的重症监护治疗时间明显更长(中位数30天对23天;p = 0.0375)。对与活动性HCMV感染相关因素的单因素检验显示,入院时发生脓毒症(p = 0.011)及在病房或外部ICU进行长时间预处理(p = 0.002)具有重要意义;潜在恶性疾病的相关性接近临界值(p = 0.059)。多元回归分析仅确定脓毒症与活动性HCMV感染独立相关(p = 0.02;比值比,4.62)。
即使在一组抗HCMV IgG血清学阳性、无明显免疫缺陷且SAPS II评分≥41分的ICU患者中,活动性HCMV感染也频繁发生(35.6%)。脓毒症患者受感染的几率是总研究人群的两倍。20例患者中有2例活动性HCMV感染进展为严重的HCMV疾病。正确诊断需要特别的临床关注并结合广泛的病毒学检查。对更大患者群体的进一步研究应评估HCMV对ICU死亡率的影响。